REDWOOD CITY, Calif.,
Dec. 6, 2017 /PRNewswire/ -- Genomic
Health, Inc. (NASDAQ: GHDX) today announced a multi-year research
collaboration agreement with Janssen Pharmaceuticals to evaluate
the Oncotype DX Genomic Prostate Score™ (GPS™) test for their
prostate cancer drug pipeline. As part of the agreement,
Genomic Health will test samples from Janssen studies to examine
the association of GPS results with clinical outcomes.
"Janssen is a recognized leader in oncology and their selection
of the Oncotype DX GPS test reflects the best-in-class value that
it delivers in stratifying patient risk and may reveal potential
for guiding treatment selection for prostate cancer patients in the
future," said Phil Febbo, M.D.,
chief medical officer, Genomic Health.
IVD Collaboration with Biocartis Strengthened
Genomic Health recently made a $4
million equity investment in Biocartis further strengthening
the partnership between the companies to develop an in vitro
diagnostic (IVD) version of the Oncotype DX Breast Recurrence
Score® test on the Idylla™ platform that can be
performed locally by laboratory partners and in hospitals around
the world.
"Our commitment to developing an IVD test with a leading
innovator like Biocartis will not only broaden global adoption and
access to Oncotype DX, but will also provide a platform that could
facilitate additional collaborations with pharmaceutical companies
seeking diagnostic partner solutions with the ability to develop
and offer tests globally through decentralized settings," said
Frederic Pla, Ph.D., chief business
and product development officer, Genomic Health.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading
provider of genomic-based diagnostic tests that help optimize
cancer care, including addressing the overtreatment of the disease,
one of the greatest issues in healthcare today. With its Oncotype
IQ® Genomic Intelligence Platform, the company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic big
data into actionable results for treatment planning throughout the
cancer patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype
DX® gene expression tests that have been used to guide
treatment decisions for more than 800,000 cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
recently launched Oncotype SEQ® Liquid
Select™ test. The company is based in Redwood City, California, with
international headquarters in Geneva, Switzerland. For
more information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
Genomic Health Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the company's beliefs
regarding its future performance and the performance of its tests;
the company's ability to develop and commercialize, and collaborate
with third parties, including Janssen Pharmaceuticals and
Biocartis, to commercialize additional tests in the future; the
potential for the research collaboration to result in any tests for
guiding treatment selection in high risk prostate cancer patients;
the company's expectations regarding timing, geographic rollout and
adoption of any tests on the Idylla platform; and the company's
ability to successfully develop an in vitro diagnostic version of
the Oncotype DX test and obtain regulatory approval of the test in
the United States and Europe. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially, and reported results should not be considered as
an indication of future performance. These risks and uncertainties
include, but are not limited to the company's ability to execute
its business model; the regulation of the company's tests or any
tests offered through its commercial channel; the applicability of
clinical study results to actual outcomes; the company's ability to
develop, commercialize or collaborate to offer any new test in new
markets domestically and internationally; the risk that sufficient
levels reimbursement may not be obtained or maintained,
domestically or abroad, for the company's tests or tests offered
through its commercial channel; competition; unanticipated costs or
delays in research and development efforts; the company's ability
or the ability of its collaborators to obtain capital when needed
to support the activities contemplated by the collaboration
described in this press release; and the other risks and
uncertainties set forth in Genomic Health's filings with the
Securities and Exchange Commission, including the risks set forth
in Genomic Health's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2017. These
forward-looking statements speak only as of the date hereof.
Genomic Health disclaims any obligation to update these
forward-looking statements.
GHDX-F
View original content with
multimedia:http://www.prnewswire.com/news-releases/genomic-health-announces-research-collaboration-with-janssen-pharmaceuticals-to-evaluate-the-oncotype-dx-genomic-prostate-score-test-for-potential-drug-development-300567499.html
SOURCE Genomic Health, Inc.